SCHEMBL1908800

SCHEMBL1908800

CCOC(=O)CCCCC(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
GAA P10253 2/20 0.48
ALDH1A1 P00352 3/20 0.46
TRPA1 O75762 1/20 0.46
ALOX15 P16050 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
DGKA P23743 1/20 0.45
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
NR1I2 O75469 1/20 0.44
PGR P06401 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
PTGS2 P35354 1/20 0.44
PDE4D Q08499 1/20 0.44
CYP4F2 P78329 2/20 0.44
CYP4A11 Q02928 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12933282 0.98 CYP1A2 (0.53) CYP1A2GAAALDH1A1TRPA1ALOX15
SCHEMBL15183506 0.98 CYP1A2 (0.53) CYP1A2GAAALDH1A1TRPA1ALOX15
SCHEMBL15183507 0.98 CYP1A2 (0.53) CYP1A2GAAALDH1A1TRPA1ALOX15
SCHEMBL15183505 0.98 CYP1A2 (0.53) CYP1A2GAAALDH1A1TRPA1ALOX15
SCHEMBL10250453 0.98 CYP1A2 (0.53) CYP1A2GAAALDH1A1TRPA1ALOX15
SCHEMBL8165697 0.94 CYP1A2 (0.57) CYP1A2GAAALDH1A1TRPA1ALOX15
SCHEMBL10081248 0.88 ALDH1A1 (0.65) CYP1A2GAAALDH1A1ALOX15TDP1
SCHEMBL3368077 0.85 ALDH1A1 (0.52) CYP1A2GAAALDH1A1TRPA1ALOX15
SCHEMBL8570508 0.84 CYP1A2 (0.73) CYP1A2GAAALDH1A1TRPA1ALOX15
SCHEMBL50610 0.84 CYP1A2 (0.73) CYP1A2GAAALDH1A1TRPA1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647747-B2 Cyclosporin derivatives and uses thereof S&T GLOBAL INC. (US) 2020-05-12 US disclosed
CN-109796308-A A kind of intermittent technique that neopentyl glycol is recycled from neopentyl glycol waste liquid 乐陵聚久环保科技有限公司 2019-05-24 CN disclosed
CN-109796334-A The intermittent technique that season senko ester is recycled from neopentyl glycol waste liquid 山东建筑大学 2019-05-24 CN disclosed
CN-109761756-A The technique for extracting neopentyl glycol and season senko ester in neopentyl glycol waste liquid 山东建筑大学 2019-05-17 CN disclosed
CN-109651088-A The method for extracting neopentyl glycol in neopentyl glycol purifying waste liquid 山东建筑大学 2019-04-19 CN disclosed
US-20180105558-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. 2018-04-19 US disclosed
US-20180105558-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. 2018-04-19 US disclosed
US-9890198-B2 Cyclosporin derivatives and uses thereof S&T GLOBAL INC. (US) 2018-02-13 US disclosed
US-20130210704-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. (US) 2013-08-15 US disclosed
US-8324239-B2 Furopyridine compounds and uses thereof NOVARTIS AG (CH) 2012-12-04 US disclosed
US-20120015907-A1 Furopyridine compounds and uses thereof NOVARTIS AG (CH) 2012-01-19 US disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7560480-B2 Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-14 US disclosed
US-7560480-B2 Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-14 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 CYP1A2 4430/4885GAA 210/4885ALDH1A1 796/4885
US-20120015907-A1 Furopyridine compounds and uses thereof CYP3A5, QDPR, DPYD CYP1A2 10/4885GAA 1023/4885ALDH1A1 178/4885
US-10647747-B2 Cyclosporin derivatives and uses thereof FKBP5, FKBP1B, MALT1 CYP1A2 805/4885GAA 1421/4885ALDH1A1 2350/4885
US-20130210704-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF FKBP1B, MALT1, FKBP5 CYP1A2 1223/4885GAA 1510/4885ALDH1A1 2376/4885
US-20180105558-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF FKBP1B, MALT1, FKBP5 CYP1A2 1223/4885GAA 1510/4885ALDH1A1 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.